Allergy Therapeutics (AGY)

 

Latest News

Publication of Annual Report and notice of AGM

RNS Number: 1267U Allergy Therapeutics PLC 19 October 2017 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING Allergy Therapeutics Plc has today published the following documents: Annual Report for the year ended 30 June 201...

Allergy Therapeutics starts dosing for grass pollen trial

Allergy Therapeutics has started its G205 phase II study designed to evaluate the dose-response and safety of its ultra-short c...

Commencement of dosing in PQ Grass Phase II Trial

RNS Number: 0102U Allergy Therapeutics PLC 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Commencement of dosing in PQ Grass Phase II Trial 19 October 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that dosing has commenced i...

Holding(s) in Company

RNS Number: 4959T Allergy Therapeutics PLC 12 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...

All News

DateHeadlineSource
19-10-17Publication of Annual Report and notice of AGMRNS
19-10-17Allergy Therapeutics starts dosing for grass pollen trial StockMarketWire
19-10-17Commencement of dosing in PQ Grass Phase II TrialRNS
12-10-17Holding(s) in CompanyRNS
12-10-17Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
12-10-17Director/PDMR ShareholdingRNS
10-10-17Allergy Therapeutics 'continuing to gain market share'StockMarketWire
10-10-17Hardman Research: Continuing to gain market shareRNS
28-09-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
28-09-17Allergy Therapeutics pre-tax losses narrow StockMarketWire
28-09-17Preliminary ResultsRNS
18-09-17Allergy Therapeutics gets approval for PQ Grass trial StockMarketWire
18-09-17Approval for PQ Grass Phase II trialRNS
11-09-17Allergy Therapeutics expands R&D and clinical team StockMarketWire
11-09-17Expansion of Clinical Development and R&D teamsRNS
15-08-17 Allergy Therapeutics schedules FY results StockMarketWire
15-08-17Notice of ResultsRNS
18-07-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
18-07-17Allergy Therapeutics ahead of forecasts StockMarketWire
18-07-17Trading UpdateRNS
06-07-17Publication of adjuvant studies in journalsRNS
27-06-17Investor and analyst site visitsRNS
19-06-17Allergy Therapeutics hosts satellite symposium at EAACIStockMarketWire
19-06-17Satellite Symposium at EAACI 2017RNS
06-06-17Directorate changesRNS
02-06-17Holding(s) in CompanyRNS
13-04-17Issue of EquityRNS
05-04-17Hardman Research: Development across portfolioRNS
04-04-17Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
29-03-17Interim Results for six months ended 31 Dec 2016RNS
16-03-17Allergy Therapeutics recruits first patient in birch pollen trial StockMarketWire
16-03-17First Patient in Pivotal Phase III Birch StudyRNS
09-03-17Notice of Interim ResultsRNS
14-02-17Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLCStockMarketWire
14-02-17Allergy Therapeutics vaccine gains CTA spprovalStockMarketWire
14-02-17House Dust Mite Allergy Vaccine Gains CTA ApprovalRNS
08-02-17Directorate ChangeRNS
01-02-17Allergy Therapeutics positive data in peanut allergy vaccineStockMarketWire
01-02-17Positive Efficacy & Safety Data in Peanut VaccineRNS
20-01-17Hardman Research: Investment driving market shareRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory